Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Town centre ‘Man Van’ prostate cancer checks boost diagnosis – research - A ‘Man Van’ mobile testing unit was sent to target ...

The government-run investor increased allocations last year to private equity and credit amid a global slowdown in dealmaking ...